Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Amir T. Fathi, Eytan M. Stein, Courtney D. DiNardo, Mark J. Levis, Pau Montesinos, Stéphane de Botton

Research output: Contribution to journalReview articlepeer-review


Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

Original languageEnglish (US)
Pages (from-to)735-746
Number of pages12
JournalAmerican journal of hematology
Issue number6
StatePublished - Jun 1 2021

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this